These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32997351)

  • 1. Impact of Plasmodium vivax malaria and antimalarial treatment on cytochrome P450 activity in Brazilian patients.
    Almeida AC; Elias ABR; Marques MP; de Melo GC; da Costa AG; Figueiredo EFG; Brasil LW; Rodrigues-Soares F; Monteiro WM; de Lacerda MVG; Lanchote VL; Suarez-Kurtz G
    Br J Clin Pharmacol; 2021 Apr; 87(4):1859-1868. PubMed ID: 32997351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.
    Brasil LW; Rodrigues-Soares F; Santoro AB; Almeida ACG; Kühn A; Ramasawmy R; Lacerda MVG; Monteiro WM; Suarez-Kurtz G
    Malar J; 2018 Feb; 17(1):57. PubMed ID: 29390987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.
    Silvino ACR; Kano FS; Costa MA; Fontes CJF; Soares IS; de Brito CFA; Carvalho LH; Sousa TN
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122891
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
    Baird JK; Louisa M; Noviyanti R; Ekawati L; Elyazar I; Subekti D; Chand K; Gayatri A; Instiaty ; Soebianto S; Crenna-Darusallam C; Djoko D; Hasto BD; Meriyenes D; Wesche D; Nelwan EJ; Sutanto I; Sudoyo H; Setiabudy R
    JAMA Netw Open; 2018 Aug; 1(4):e181449. PubMed ID: 30646129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.
    Martin Ramírez A; Lombardia González C; Soler Maniega T; Gutierrez Liarte Á; Domingo García D; Lanza Suárez M; Bernal Fernández MJ; Rubio JM
    Malar J; 2020 Jul; 19(1):259. PubMed ID: 32680522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
    St Jean PL; Xue Z; Carter N; Koh GC; Duparc S; Taylor M; Beaumont C; Llanos-Cuentas A; Rueangweerayut R; Krudsood S; Green JA; Rubio JP
    Malar J; 2016 Feb; 15():97. PubMed ID: 26888075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients.
    Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Cho SH; Lee SE; Kwon JR; Park S; Kim M; Oh HS; Kim YC; Kim MJ; Yeom JS
    Malar J; 2022 Oct; 21(1):289. PubMed ID: 36217154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine.
    Daher A; Aljayyoussi G; Pereira D; Lacerda MVG; Alexandre MAA; Nascimento CT; Alves JC; da Fonseca LB; da Silva DMD; Pinto DP; Rodrigues DF; Silvino ACR; de Sousa TN; de Brito CFA; Ter Kuile FO; Lalloo DG
    Malar J; 2019 Sep; 18(1):325. PubMed ID: 31547827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function.
    Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Oh HS; Kim YC; Yeom JS; Han JH; Kim MJ
    Korean J Parasitol; 2022 Feb; 60(1):39-43. PubMed ID: 35247953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses.
    Puça MCSB; Rodrigues DF; Salazar YEAR; Louzada J; Fontes CJF; Daher A; Pereira DB; Fernandes Vieira JL; Carvalho LH; Alves de Brito CF; Gil JP; Nobrega de Sousa T
    J Antimicrob Chemother; 2024 Aug; 79(8):1985-1989. PubMed ID: 38870082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of CYP2D6 Genetic Variation on Radical Cure of Plasmodium vivax Malaria.
    Suarez-Kurtz G
    Clin Pharmacol Ther; 2021 Sep; 110(3):595-598. PubMed ID: 34042179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor.
    Chen N; Dowd S; Gatton ML; Auliff A; Edstein MD; Cheng Q
    Malar J; 2019 Apr; 18(1):140. PubMed ID: 30999967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 and P-glycoprotein probe substrates and their metabolites using subtherapeutic doses.
    Cusinato DAC; Filgueira GCO; Rocha A; Cintra MACT; Lanchote VL; Coelho EB
    J Pharm Biomed Anal; 2019 Feb; 164():430-441. PubMed ID: 30445356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
    Baird JK; Battle KE; Howes RE
    Malar J; 2018 Jan; 17(1):42. PubMed ID: 29357870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19.
    Tamminga WJ; Wemer J; Oosterhuis B; Brakenhoff JP; Gerrits MG; de Zeeuw RA; de Leij LF; Jonkman JH
    Eur J Clin Pharmacol; 2001 May; 57(2):143-6. PubMed ID: 11417446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enantioselective metabolism of primaquine by human CYP2D6.
    Fasinu PS; Tekwani BL; Nanayakkara NP; Avula B; Herath HM; Wang YH; Adelli VR; Elsohly MA; Khan SI; Khan IA; Pybus BS; Marcsisin SR; Reichard GA; McChesney JD; Walker LA
    Malar J; 2014 Dec; 13():507. PubMed ID: 25518709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primaquine in Plasma and Methemoglobinemia in Patients with Malaria Due to
    Vieira JL; Ferreira MES; Ferreira MVD; Gomes MM
    Am J Trop Med Hyg; 2017 May; 96(5):1171-1175. PubMed ID: 28440745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450 2D6 profiles and anti-relapse efficacy of tafenoquine against
    Dowd S; Chen N; Gatton ML; Edstein MD; Cheng Q
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0101423. PubMed ID: 37971260
    [No Abstract]   [Full Text] [Related]  

  • 19. Case report: recurrence of Plasmodium vivax malaria due to defective cytochrome P450 2D6 function in Pos Lenjang, Pahang, Malaysia.
    Mat Salleh NH; Rahman MFA; Samsusah S; De Silva JR; Ng DC; Ghozali AH; Tan JH; Lai MY; Amir A; Liew JWK; Lau YL
    Trans R Soc Trop Med Hyg; 2020 Sep; 114(9):700-703. PubMed ID: 32511702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment.
    Pereira D; Daher A; Zanini G; Maia I; Fonseca L; Pitta L; Ruffato R; Marchesini P; Fontes CJ
    Malar J; 2016 Sep; 15():477. PubMed ID: 27639847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.